By Martha Cabrales Arias Santiago de Cuba, Jan 8 (Prensa Latina) Laboratorios DALMER S.A. is expanding its potentialities for Cuban and foreign medicine, even when is already one of the leaders in this export sector in Cuba, said its director, Dr. Rafael Gámez.
In these sense, Gámez highlighted the first soft-capsule plant in the country, which is in the final phase of its construction for the production of Palmex, a product already registered and effective in the treatment of benign prostatic hyperplasia.
The scientist added that this nutritional supplement, a lipid extract of the royal palmÂ´s fruit with antioxidant properties, was subjected to a rigorous experimentation process and in particular to toxicological studies that favor the application for registration as a medicine of natural origin.
He also mentioned the advances in the researches to obtain an oral vaccine against cholera, which is in the phase of clinical trials and was carried out in collaboration with the Finlay Institute.
The director also highlights the opening to marketing to third parties, beyond the National Center for Scientific Research (Cenic), to which they belong; and referred to these efforts with BioCen, HeberBiotec, the Center for Genetic Engineering and Biotechnology and the University of Havana.